Your browser doesn't support javascript.
loading
Biodegradable Local Chemotherapy Platform with Prolonged and Controlled Release of Doxorubicin for the Prevention of Local Tumor Recurrence.
Voznyuk, Amina A; Makarets, Yulia A; Advakhova, Darya Yu; Khafizov, Krestina A; Lugovoi, Maksim E; Zakharova, Vasilina A; Senatov, Fedor S; Koudan, Elizaveta V.
Afiliação
  • Voznyuk AA; National University of Science and Technology MISIS, Leninskiy pr. 4, Moscow 119049, Russian Federation.
  • Makarets YA; National University of Science and Technology MISIS, Leninskiy pr. 4, Moscow 119049, Russian Federation.
  • Advakhova DY; National University of Science and Technology MISIS, Leninskiy pr. 4, Moscow 119049, Russian Federation.
  • Khafizov KA; Haute École de la Province de Namur, Henri Blès st. 192, Namur 5000, Belgium.
  • Lugovoi ME; National University of Science and Technology MISIS, Leninskiy pr. 4, Moscow 119049, Russian Federation.
  • Zakharova VA; National University of Science and Technology MISIS, Leninskiy pr. 4, Moscow 119049, Russian Federation.
  • Senatov FS; National University of Science and Technology MISIS, Leninskiy pr. 4, Moscow 119049, Russian Federation.
  • Koudan EV; National University of Science and Technology MISIS, Leninskiy pr. 4, Moscow 119049, Russian Federation.
ACS Appl Bio Mater ; 7(4): 2472-2487, 2024 04 15.
Article em En | MEDLINE | ID: mdl-38480461
ABSTRACT
Local recurrence after surgical and therapeutic treatment remains a significant clinical problem in oncology. Recurrence may be due to imperfections in existing therapies, particularly chemotherapy. To improve antitumor activity and prevent local cancer recurrence while keeping toxicity at acceptable levels, we have developed and demonstrated a biodegradable local chemotherapy platform that provides controlled and prolonged drug release. The platform consists of a polycaprolactone (PCL) substrate, which provides the structural integrity of the platform and the predominant unidirectional drug release, and a thin multilayer coating (∼200 nm) containing doxorubicin (DOX). The coating is an electrostatic complex obtained by the layer-by-layer (LbL) assembly and consists of natural polyelectrolytes [poly-γ-glutamic acid (γ-PGA) and chitosan (CS) or poly-l-lysine (PLL)]. To improve the release stability, an ionic conjugate of DOX and γ-PGA was prepared and incorporated into the multilayer coating. By varying the structure of the coating by adding empty (without DOX) bilayers, we were able to control the kinetics of drug release. The resulting platforms contained equal numbers of empty bilayers and DOX-loaded bilayers (15 + 15 or 30 + 30 bilayers) with a maximum loading of 566 ng/cm2. The platforms demonstrated prolonged and fairly uniform drug release for more than 5 months while retaining antitumor activity in vitro on ovarian cancer cells (SKOV-3). The empty platforms (without DOX) showed good cytocompatibility and no cytotoxicity to human fibroblasts and SKOV-3 cells. This study presents the development of a local chemotherapy platform consisting of a PCL-based substrate which provides structural stability and a biodegradable polyelectrolyte layered coating which combines layers containing a polyanion ionic complex with DOX with empty bilayers to ensure prolonged and controlled drug release. Our results may provide a basis for improving the efficacy of chemotherapy using drug delivery systems.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Nanopartículas / Recidiva Local de Neoplasia Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Nanopartículas / Recidiva Local de Neoplasia Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article